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Osteoarthritis (OA) is the leading cause of joint disease 
in humans. Its complex pathogenesis remains poorly 
under  stood but appears multifactorial. OA is slowly 
progres  sive and involves all components of the joint, 
including bone, cartilage, meniscus and synovium. No 
speciﬁ  c therapy has been identiﬁ  ed to reverse or retard 
the consequences of OA. Th  erefore, joint replacement 
surgery is often ultimately the only therapeutic option. It 
is within this context that the recent work of Sun and 
colleagues [1] is both novel and clinically relevant.
Calciﬁ   cation of articular cartilage (both hyaline and 
meniscal) is a well recognized feature of OA and current 
evidence suggests that it contributes directly to joint 
degeneration [2]. Calcium-containing crystals are found in 
more than 60% of synovial ﬂ  uid samples from un  selected 
OA patients at knee arthroplasty [3]. Although ample in 
vitro evidence demonstrates the potent bio  logical eﬀ  ects of 
calcium-containing crystals, contro  versy exists as to 
whether these crystals play a causal role, or are merely a 
consequence of the joint damage seen in OA [2].
Calcium pyrophosphate dihydrate (CPPD) and basic 
calcium phosphate (BCP) are the two most common 
forms of calcium crystals found in articular cartilage [4]. 
Th  eir presence is associated with a number of clinical 
manifestations. For example, CPPD crystals cause acute 
attacks of articular pseudogout [5] and the presence of 
intra-articular BCP crystals correlates strongly with the 
severity of radiographic OA [6]. Both types of crystals are 
found in OA, but data on the distribution and frequency 
of BCP crystals vary considerably, mainly due to the lack 
of simple and reliable methods of detection [7]. Further-
more, the precise source of these crystals is unclear. 
Recent work clearly demonstrates that BCP is the pre-
dominant crystal type in OA hyaline cartilage, and that 
chondrocytes derived from OA hyaline cartilage produce 
BCP crystals in vitro [7]. Th  is suggests that cartilage 
mineralisation with BCP crystals by chondrocytes is part 
of the disease process in OA.
While meniscal degeneration and calciﬁ  cation are key 
features of OA knee joints [8], few studies have investi-
gated the potential role of OA meniscal cells in the 
pathogenesis of OA. In addressing this neglected area, 
the work by Sun and colleagues demonstrates a number 
of key ﬁ   ndings. First, calcium crystal deposition is 
common in the menisci of end-stage OA patients and the 
pattern of calciﬁ   cation seen is diﬀ   erent from that of 
primary chondrocalcinosis. Secondly, OA meniscal cells, 
when cultured, induce signiﬁ   cantly more calcium 
deposition than normal control meniscal cells. Th  irdly, 
the expression of genes known to cause articular calciﬁ  -
cation (ANKH and ENPP1) is upregulated in OA menis-
cal cells. Finally, calcium deposition by OA meniscal cells 
is inhibited by phosphocitrate, an observation that is also 
supported by complementary work using an animal 
model of OA [9].
In assessing the potential impact of this study by Sun 
and colleagues, the following methodological weaknesses 
should be considered. Identiﬁ  cation of the speciﬁ  c type 
of crystals (CPPD or BCP) present in both the clinical 
samples and the cultured cells was not established. 
Further  more, the phenotype of the meniscal cells used in 
the cultured samples and potential diﬀ  erences between 
OA meniscal cells and control cells are not addressed. 
Abstract
Articular calcifi  cation correlates with osteoarthritis 
(OA) severity but its exact role in the disease process is 
unclear. In examining OA meniscal cell function, Sun 
and colleagues have shown recently that meniscal 
cells from end-stage OA subjects can generate calcium 
crystals and that genes involved in calcifi  cation are 
upregulated in OA meniscal cells. Also, this in vitro 
calcium deposition by OA menisci is inhibited by 
phosphocitrate. This study should catalyse further work 
examining the pathological contribution or otherwise 
of calcium crystals in OA. This would signifi  cantly 
aid the development of potential disease modifying 
agents in OA, which are currently unavailable.
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produce type X collagen, a recognised marker of chon-
dro  cyte hypertrophy and strongly associated with the 
production of calcium crystals by hyaline cartilage [7]. 
Th   is is important, as previous work clearly distinguishes 
speciﬁ   c phenotypes of meniscal cells (with diﬀ  erent 
functional capabilities) in OA menisci compared to 
normal menisci [10]. An age-related calciﬁ  cation eﬀ  ect 
also cannot be excluded on the basis of the relatively 
small sample sizes used. Finally, as correctly stated by the 
authors, the ﬁ  ndings of the study do not prove a causal 
role for calcium crystal deposition in OA.
Nonetheless, meniscal calciﬁ   cation, mediated by 
meniscal cells, is a potentially important contributory 
factor in the pathogenesis of OA. Th  erefore, notwith-
standing the limitations noted above, the clinical rele-
vance of this study is timely. To truly test the hypothesis 
that calcium crystals play a causative role in OA, animal 
studies in which these crystals (especially BCP) are 
injected intra-articularly are warranted [2]. Should such 
studies demonstrate the induction or acceleration of joint 
degeneration that could then be arrested or reversed by 
an agent such as phosphocitrate, this would provide 
proof-of-concept evidence for the pathogenicity or 
otherwise of these crystals in OA.
A major barrier to developing medical interventions in 
OA has been the reliance on end-stage radiographic 
outcome measures, which often take years to develop and 
are therefore unsuitable for placebo-controlled trials. Th  e 
adoption of articular cartilage calciﬁ  cation as a surrogate 
marker of OA disease, coupled with the development of 
improved detection methods for BCP crystals, could 
enable trials of targeted anti-crystal therapies with 
biological endpoints and a fast turnaround time. Th  is 
could signiﬁ   cantly advance the search for an eﬀ  ective 
medical intervention in the most common of human 
joint disorders.
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